Lymphoma

A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer, according to study results published in JCO Oncology Practice.

Pembrolizumab plus gemcitabine, vinorelbine and liposomal doxorubicin demonstrated substantial efficacy as second-line therapy among patients with relapsed or refractory classical Hodgkin lymphoma, according to phase 2 study results.

Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.

CRISPR may be the most notable name in the world of gene editing, but it’s not the only option.

An experimental first-line regimen significantly extended PFS compared with standard of care for patients with diffuse large B-cell lymphoma, topline results of a randomized phase 3 trial showed.

Bristol Myers Squibb withdrew the indication for romidepsin as treatment for relapsed or refractory peripheral T-cell lymphoma.

Zanubrutinib prolonged PFS compared with bendamustine plus rituximab among patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma who did not harbor deletion 17p.

The FDA in February approved lisocabtagene maraleucel — a chimeric antigen receptor T cell therapy — for treatment of relapsed or refractory diffuse large B-cell lymphoma.

Some survivors of Hodgkin lymphoma included in the Mass General Brigham YOUNG-MI registry experienced a myocardial infarction before age 50 years, according to a research letter published in JACC: CardioOncology.

ASH will present honorific awards to several hematologists during this year’s ASH Annual Meeting, scheduled for Dec. 11-14.